pomalidomide

01/01/2022 - "Pomalidomide, a kind of immunomodulatory drug, is widely used for the treatment of relapsed or refractory multiple myeloma and could be administered without dose modification in patients with renal dysfunction. "
04/01/2013 - "Effective treatment of pomalidomide in central nervous system myelomatosis."
02/01/2022 - "Aim: To demonstrate the efficacy of pomalidomide for relapsed/refractory multiple myeloma (RRMM) following treatment in real-world, community practice using retrospective database analysis. "
01/01/2023 - "Alternate-day dosing of pomalidomide in relapsed/ refractory multiple myeloma: a multicenter, single-arm phase 2 trial."
01/01/2019 - "Pomalidomide-Based Regimens for Treatment of Relapsed and Relapsed/Refractory Multiple Myeloma: Systematic Review and Meta-analysis of Phase 2 and 3 Clinical Trials."

01/01/2021 - "The combination of BCMA-CD3 BsAb with pomalidomide expanded lytic T cells and improved activity even in IMiD resistant high-tumor burden cases. "
12/01/2018 - "Knockout of PD-L1 on tumor cells or in mice completely eliminated the immunomodulatory effect of pomalidomide. "
01/01/2021 - "A phase 1 first in pediatric trial of pomalidomide was conducted in children with recurrent, progressive, and refractory CNS tumors. "
04/01/2014 - "A simple and robust HPLC assay with fluorescence detection for pomalidomide over the range of 1-500ng/mL has been developed for application to pharmacokinetic studies in ongoing clinical trials in various other malignancies. "
11/01/2012 - "Phase I trial of pomalidomide given for patients with advanced solid tumors."

08/01/2011 - "The combination of symptoms, radiographic findings, clinical course, and response to treatment strongly supports the diagnosis of acute pulmonary toxicity secondary to pomalidomide. "
04/01/2014 - "Moreover, compared with high-dose dexamethasone, treatment with pomalidomide plus low-dose dexamethasone significantly prolonged progression-free survival, overall survival and time to disease progression, and improved overall response rates in the intent-to-treat population. "
10/01/2023 - "Oral pomalidomide (4 mg once daily; days 1-21) and dexamethasone (40 mg once daily; days 1, 8, 15, and 22) were given in 28-day cycles until disease progression or unacceptable toxicity. "
12/13/2018 - "All patients received pomalidomide-dexamethasone maintenance until disease progression. "
09/01/2017 - "Patients received 28-day cycles of pomalidomide 4 mg/day on days 1-21 and low-dose dexamethasone 40 mg (20 mg if aged > 75 years) weekly until disease progression or unacceptable toxicity. "

01/01/2015 - "Five major pomalido-mide clinical trials have been completed to date, and demonstrate tolerability and efficacy with low-dose pomalidomide (0.5 mg/day) in the treatment of myelofibrosis, and no clinical benefit of elevated dosing regimens (≥2.5 mg/day). "
02/01/2011 - "A phase-2 trial of low-dose pomalidomide in myelofibrosis."
02/01/2010 - "Phase1/-2 study of Pomalidomide in myelofibrosis."
01/01/2017 - "Responses to pomalidomide and placebo in myelofibrosis-related anaemia."
01/01/2017 - "Response in the pomalidomide cohort was associated with ⩽4 U RBC/28 days (odds ratio (OR)=3.1; 0.9, 11.1), age ⩽65 (OR=2.3; 0.9, 5.5) and type of MPN-associated myelofibrosis (OR=2.6; 0.7, 9.5). "

02/01/2011 - "Low-dose pomalidomide is effective in the treatment of anemia associated with JAK2V617F-positive MF; response is predicted by early drug-induced basophilia."
01/01/2011 - "Pomalidomide appears to be particularly active against MF-associated anemia. "
12/01/2013 - "In parallel, phase III testing of pomalidomide is ongoing, with the goal of solidifying the role of immunomodulatory therapy in MF-associated anemia. "
08/01/2012 - "Pomalidomide's good anemia response may lead to its inclusion as one of the frontline anemia therapies in MF. "
01/01/2018 - "Significant improvements in anemia and thrombocytopenia were observed with pomalidomide, and the patient recovered from transfusion dependence for 8 months. "